Predictive factors for response to @entity17931 in metastatic XXXX .

@entity1 @entity17931 @entity263 @entity342 @entity1349 @entity1486
BACKGROUND: Management of metastatic @entity263 ( @entity263 ) is rapidly evolving. Rationalisation of treatment requires identification of those @entity1 more likely to benefit from a particular therapy. We reviewed the outcome of @entity1 treated with @entity17931 at our Institution to describe factors predictive for response. @entity1 AND METHODS: @entity1 with CRCP treated with @entity17931 were identified. Baseline variables and potential prognostic factors were extracted from electronic records. Outcome measures included @entity1349 ( @entity1349 ), @entity1486 (PSA) response and time to PSA progression (TTPP). The Kaplan-Meier method and Cox proportional hazards model were used to analyze survival data. RESULTS: A total of 61 @entity1 met the inclusion criteria. In multivariate analysis, three independent predictors of @entity1349 were identified: Duration of response to @entity342 deprivation therapy (ADT) (hazard ratio(HR)=0.95, p=0.006), performance status (HR=7.4, p=0.013), and baseline haemoglobin (HR=0.47, p <=0.001). CONCLUSION: This study has identified three factors predictive for response to @entity17931 in @entity263 . Duration of response to ADT has not been previously shown to be a predictive factor for @entity1 with CRCP. We suggest that a prospective validation is required.
